- American Indian Living Radio Suwanee, GA, Oct. 9, 2018
- Association of American Indian Physicians Conference Scottsdale, AZ, July 26-28, 2018
- 9th Annual Tribal Public Health Summit Prior Lake, MN, May 22-24, 2018
- VA Healthcare Oxen Hill, MD, May 14-16, 2018
- Tribal Public Health Conference Norman, OK, April 25-26, 2018
- SANUWAVE Announces Strategic Partnership With Premier Shockwave Feb 13, 2018
Premier Shockwave to Exhibit at VA Healthcare in Oxen Hill, MD, May 14-16, 2018
SUWANEE, GA, May 7, 2018 (GLOBE NEWSWIRE) – Premier Shockwave, Inc. is pleased to announce that the company will exhibit at VA Healthcare in the MGM National Harbor in Oxen Hill, MD, May 14 – 16, 2018. This will be Premier Shockwave’s first opportunity to present the dermaPACE® System since being selected by SANUWAVE Health, Inc. as its exclusive distributor to the Veterans Administration (VA) healthcare services market.
“We are excited to be exhibiting at VA Healthcare 2018. It is an honor to be able to help our Veterans and to bring a game-changing product to this market which will materially improve patient outcomes, and quality of life, for those suffering from chronic diabetic foot ulcers. The dermaPACE® will enable VA physicians to improve healing rates and outcomes. This will save thousands of dollars per DFU treated by the VAs.” Stated David Anderson, Executive Vice President of Premier Shockwave Wound Care, Inc. an affiliate of Premier Shockwave, Inc. He added, “Any physician who sees DFUs can prescribe the dermaPACE®, not only podiatrists, we expect to see interest from endocrinologists, vascular surgeons, foot & ankle orthopedists to have their nurse assistants trained to use the dermaPACE® on their patients in a wound care facility or an in-office setting.”
The Company is using this occasion to formally introduce their lead wound care product, the dermaPACE® System. This Focused Electro-Hydraulic Extracorporeal Shockwave Technology (FEHSW) device, has been proven in two US based clinical trials enrolling 336 subjects to be safe and effective in the treatment of Diabetic Foot Ulcers. Within a few weeks of initial treatment, wounds treated with dermaPACE® reduce in area at superior rates compared to control subjects. The dermaPACE® System exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment. The use of the dermaPACE® System allows the clinician to more easily, and more cost-effectively, manage wounds. More importantly, the patient’s quality of life improves significantly.
If you are interested in scheduling a meeting with the team, please contact Josh Winter, Vice President of Business Development via e-mail at firstname.lastname@example.org; otherwise, please stop by our booth.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a focused electro-hydraulic shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
About Premier Shockwave, Inc. and Premier Shockwave Wound Care, Inc.
Premier Shockwave, Inc. is the leading shockwave company for podiatric and orthopedic applications using OssaTron® and dermaPACE® devices throughout the United States and currently serves over 30 VA Hospitals and Military Treatment Facilities in the continental United States and Alaska. Premier Shockwave, Inc. will manage the dermaPACE® business for Premier Shockwave Wound Care, Inc. For additional information about the company, please go to www.premiershockwave.com.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit